Company Overview and News

3
U.S. health secretary says agency has power to eliminate drug rebates

16h reuters
WASHINGTON (Reuters) - U.S. Health and Human Services Secretary Alex Azar said it was within his agency’s power to eliminate rebates on prescription drug purchases, a key element of the Trump administration’s plan to lower prescription medicine costs.
PFZ CELGZ CELG 500680 PFE PFIZER

8
Apple, Caterpillar Dominate the Dow Friday

2018-08-17 247wallst
August 17, 2018: Markets opened mixed Friday but all three major indexes are pointed at a positive close for the day. Sanctions on Iran are said to include penalties as well for countries currently buying oil from the Islamic Republic. That would include China with which the United States is scheduled to begin trade talks next week. All 11 S&P sectors are trading in the green ahead of the close with industrials and consumer staples performing best.
PFZ CATR CAT AAPL CSCO 500680 PFE PFIZER

5
EpiPen shortage has parents struggling during back-to-school season

2018-08-17 cnbc
Brenda Thiel and Alyssa Wachtler live on opposite sides of the country. But they've got at least one thing in common: both have sons with severe nut allergies. And when they made their usual back-to-school trips to the pharmacy to procure their EpiPens for the new year, they were told the same thing.
WFC WFCNP PFZ PFIZER 500680 PFE

1
Pfizer Limited - Appointment

2018-08-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
PFZ 500680 PFE PFIZER

10
Why Merrill Lynch Sees Health Care Sector Offering Solid Growth, and as Value and Defensive

2018-08-15 247wallst
Each month brings new views from firms on Wall Street. This includes the actively followed RIC Report from Merrill Lynch, showing views on many sectors and many markets for the firm’s clients. The monthly RIC Report is quite favorable on the health care sector as an opportunity for investors.
PFZ AMGN MRK A ABBV 500680 PFE PFIZER ABBV

6
Current Bull Market Not Over Until It’s Over: 5 US Stocks to Buy

2018-08-15 247wallst
It may be hard to believe, but on August 23, according to Merrill Lynch, the current bull market will be the longest in history, reaching back to the lows printed in March of 2009. While some would argue that the actual secular bull market didn’t start until the S&P 500 broke out above 1,550 in March of 2013, that in and of itself, was over five years ago.
PFZ C ANAC PFIZER CGBBW 500680 PFE

1
EpiPen shortage could turn into crisis as back-to-school season hits - MarketWatch

2018-08-14 marketwatch
Mylan’s EpiPen was first added to the FDA’s drug shortage list in May, but supply issues continue
PFZ 500680 PFE PFIZER

28
Startups Turning Office Market Upside Down by Offering Short-Term Leases - WSJ

2018-08-14 wsj
A startup real-estate technology firm is looking to take on shared office company WeWork Cos in one of hottest new areas of commercial real estate: providing short-term office space to some of the biggest U.S. companies.
BPY CCV CCZ FMCKI FMCKJ UBS CMCSK IBM H FMCCO PFZ FMCCP FMCCM FMCCN CMCSA FMCCI FMCCJ P FMCCG FMCKO FMCKP FMCKM FMCKN PFIZER FMCKK FMCKL FMCC CCV.CL MSFT 500680 PFE FMCCS ULSGF FMCCT

1
A Quality Driven Dividend Growth Portfolio - Pfizer Inc.

2018-08-13 seekingalpha
This portfolio is about choosing stocks based on a quality metric score and determining whether to buy based on a purchase metric score.
PFZ 500680 PFE PFIZER

17
Shire, Shionogi File NDA for Intuniv for Adults in Japan

2018-08-13 zacks
Shire Plc. (SHPG - Free Report) announced that its Japanese partner Shionogi & Co., Ltd submitted a new drug application (NDA) for the manufacture and marketing of Intuniv (guanfacine hydrochloride extended release) in Japan for the treatment of attention deficit hyperactivity disorder (ADHD) in adults. Intuniv is being co-developed and commercialized by Shire and Shionogi under a licensing contract signed in 2011.
FOX PFZ GILD JNJ LMHA 500680 PFE LMHB FOXA PFIZER LM

1
Generic Drugmakers Struggle Despite U.S. Push for Copycats - Bloomberg

2018-08-09 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
PFZ 500680 PFE PFIZER

34
CEF Opportunity: 5.5% Yield, 20% Upside, Well-Positioned For Rising Rates, Diversified Holdings

2018-08-09 seekingalpha
I love Mario Gabelli. I have been following him from the first time I saw him speak on CNBC. He has a knack for picking great stocks.
CVS HON 8685 STT AVF PNCFO GDV WM AIG PFIZER PNC SWMAF VZ BA PFE WFCNP SWMAY VZA BOE XYL WFC HON PFZ DWDP PEP PNUCL 500680

44
Disney, Pfizer Keep the Dow Flat Wednesday

2018-08-08 247wallst
August 8, 2018: Markets opened narrowly mixed Wednesday and looks set to end the regular trading session the same way. The blue-chip Dow index traded lower all day while the S&P 500 and the Nasdaq Composite are holding onto slim gains. The Trump trade war with China experienced another skirmish yesterday, but corporate earnings reports continue to offset investors’ fears. The energy sector lagged today while the tech and financial services sectors posted the best gains.
PFZ CATR CAT 500680 PFE PFIZER MCD DIS

3
Protagonist Stock Jumps 58% After Re-Review of Test Results

2018-08-08 investorplace
The mouth-watering 58% rise in shares of Protagonist Therapeutics (NASDAQ:PTGX) on Monday should interest biotech investors. The rally is a welcome change after months of PTGX stock going nowhere.
PFZ CELG PTGX 500680 PFE PFIZER

1
UPDATE 1-Trump says will make announcement next week on reducing drug prices

2018-08-08 reuters
BEDMINSTER, N.J. (Reuters) - U.S. President Donald Trump said on Tuesday that his administration would make an announcement next week on reducing drug prices, but he did not offer specifics.
PFZ 500680 PFE PFIZER

Related Articles

REPH: Recro Pharma Analysis and Research Report

23h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

23h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...